Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Oct 02, 2023
Ticker Group $DYNT, $ANGO, $AMEH, $OPRX: Physicians Group Companies Surge +4.41% in Weekly Performance

Ticker Group $DYNT, $ANGO, $AMEH, $OPRX: Physicians Group Companies Surge +4.41% in Weekly Performance

For the Physicians group companies, which include DYNT (Dynatronics), ANGO (AngioDynamics), AMEH (Apollo Medical Holdings), and OPRX (OptimizeRx), the past week has been marked by a significant increase in performance, with a collective gain of +4.41%. However, a deeper look into various indicators and metrics suggests a challenging road ahead for these stocks.

The Theme and Group of Tickers

The Physicians group companies represent a collection of healthcare-related stocks that have recently experienced a notable increase in performance. This group comprises DYNT, ANGO, AMEH, and OPRX, all of which are engaged in various aspects of the healthcare industry. While their recent performance is noteworthy, it is essential to consider other factors that might affect their future prospects.

Stock Outlook and Aroon Indicator

As of the latest data, these stocks carry a Negative Outlook, a sentiment backed by the Aroon Indicator. This indicator, a popular technical analysis tool, suggests that the current trend for these stocks might not be favorable. It's worth noting that technical indicators like the Aroon Indicator are just one piece of the puzzle when evaluating stocks.

Stock Fear & Greed Index

The Stock Fear & Greed Index, provided by Tickeron, indicates a negative outlook for this group. Tickeron predicts a further decline of more than 4.00% within the next month, with an 81% likelihood. This pessimistic forecast underscores the uncertainty surrounding these stocks. During the last month, the daily ratio of advancing to declining volumes for this group was 1 to 1.84, indicating a mixed sentiment among investors.

TrendMonth Indicator

Four stocks within this group exhibit a similar negative trend based on the TrendMonth indicator, with an average likelihood of 79%. This indicator suggests that the negative sentiment is widespread across the group, further highlighting the challenges these companies face.

Market Cap

The market capitalization of the Physicians Theme averages around $469.8 million. Within this group, market caps range from $2.8 million for DYNT to $1.5 billion for AMEH. This substantial variation in market capitalization reflects the diversity of companies within the theme, with AMEH being the highest valued and DYNT the lowest.

High and Low Price Notable News

In terms of price movements, DYNT experienced the highest weekly price growth at 7.02%, while AMEH faced the most significant fall at 3.04%. Such price fluctuations in the healthcare sector can be influenced by various factors, including industry-specific news, regulatory changes, and economic conditions.

Volume Trends

Volume trends are also a crucial aspect of stock analysis. While the average weekly volume growth for these stocks was 7.93%, the average monthly and quarterly volume growth rates were -29.88% and -62.48%, respectively. These figures indicate varying levels of investor interest and activity in these stocks over different timeframes.

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows:

  • Valuation Rating: 71
  • P/E Growth Rating: 48
  • Price Growth Rating: 87
  • SMR Rating: 87
  • Profit Risk Rating: 93
  • Seasonality Score: -15

These ratings give investors a snapshot of how these companies are fundamentally positioned, with a particular focus on valuation, profitability, and growth potential.

Individual Stock Analysis

  1. ANGO's Indicator enters downward trend: The Aroon Indicator for ANGO has entered a downward trend, suggesting potential downside. Tickeron's analysis indicates an 84% probability of a downward move.

  2. OPRX's Indicator enters downward trend: Similarly, the Aroon Indicator for OPRX signals a potential downward trend, with an 84% probability of a decline.

  3. DYNT's RSI Oscillator climbs out of oversold territory: DYNT's RSI Oscillator has moved out of oversold territory, suggesting a possible shift from a downward to an upward trend. Tickeron's analysis indicates a 90% probability of an upward move.

In summary, while the Physicians group companies have recently shown a positive uptick in performance, there are several warning signs, including technical indicators and negative sentiment, that suggest potential challenges in the near future. Investors should exercise caution and conduct thorough research before making any investment decisions in these stocks, considering both short-term and long-term prospects. The healthcare sector, like any other, is subject to a complex web of factors that can influence stock performance, making comprehensive analysis crucial for informed decision-making.

Related Ticker: OPRX, ANGO, DYNT, AMEH

Contributor

Dem Sem's AvatarDem Sem|Expert

OPRX in downward trend: price may decline as a result of having broken its higher Bollinger Band on August 13, 2026

OPRX broke above its upper Bollinger Band on August 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 35 similar instances where the stock broke above the upper band. In of the 35 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for OPRX moved out of overbought territory on August 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where OPRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on OPRX as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for OPRX just turned positive on August 05, 2026. Looking at past instances where OPRX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where OPRX advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 136 cases where OPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.108) is normal, around the industry mean (7.638). P/E Ratio (30.840) is within average values for comparable stocks, (46.808). OPRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.726). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (1.496) is also within normal values, averaging (6.460).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.95B. The market cap for tickers in the group ranges from 708 to 40.27B. VEEV holds the highest valuation in this group at 40.27B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 25%. TEM experienced the highest price growth at 40%, while ONMD experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -51% and the average quarterly volume growth was -90%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 98
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
OPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products

Industry ServicestotheHealthIndustry

Profile
Details
Industry
Data Processing Services
Address
260 Charles Street
Phone
+1 248 651-6568
Employees
133
Web
https://www.optimizerx.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.